NIH prepares to launch 2009 H1N1 influenza vaccine trial in people with asthma
The National Institutes of Health is preparing to launch the first government-sponsored clinical trial to determine what dose of the 2009 H1N1 influenza vaccine is needed to induce a protective immune response in people with asthma, especially those with severe disease. The study is cosponsored by the National Institute of Allergy and Infectious Diseases (NIAID) and the National Heart, Lung, and Blood Institute (NHLBI), both part of NIH.
NIH launches 2009 H1N1 influenza vaccine trials in HIV-infected pregnant women
The first clinical trials to test whether the 2009 H1N1 influenza vaccine can safely elicit a protective immune response in pregnant women launched yesterday, and a trial to conduct the same test in HIV-infected children and youth will begin next week. The International Maternal Pediatric Adolescent AIDS Clinical Trials Group is conducting the studies, which are sponsored and funded by the National Institute of Allergy and Infectious Diseases (NIAID) and the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), both part of the National Institutes of Health. more
Breast cancer patients with high risk gene diagnosed 6 years earlier than generation before
Women with a deleterious gene mutation are diagnosed with breast cancer six years earlier than relatives of the previous generation who also had the disease and/or ovarian cancer, according to new research from The University of Texas M. D. Anderson Cancer Center. more
Researchers report benefits of new standard treatment study for rare pediatric brain cancer
A team of researchers led by The University of Texas M. D. Anderson Cancer Center unveiled results today from the largest-ever collaborative study addressing the treatment of a rare pediatric brain tumor. The findings suggest a new standard protocol could improve survival nearly two-fold for pediatric patients with choroid plexus tumors, as reported at the 41st Annual Meeting of the International Society of Pediatric Oncology (SIOP). more
Hormone therapy for prostate cancer may pose heart risks
The largest study of its kind indicates that hormone treatments used to block the effects of testosterone on prostate tumors can increase the risk of cardiac events and cardiac death. The retrospective study reviewed the health records of more than 30,000 Swedish men and found that the risk was highest in those men taking gonadotropin-releasing hormone (GnRH) agonists, the most commonly used hormone treatment in the United States. The results were reported at the ECCO 15-ESMO 34 conference in Germany.
Breast cancer trial suspends recruitment
An NCI-sponsored phase III clinical trial for women with high-risk breast cancer has temporarily suspended accrual while researchers study the incidence of congestive heart failure among participants. The E5103 trial is comparing bevacizumab (Avastin) combined with standard adjuvant chemotherapy versus adjuvant chemotherapy alone for women with lymph node-positive or high-risk lymph node-negative breast cancer who have undergone lumpectomy or mastectomy. more
High-dose daunorubicin benefits younger adults with leukemia
In two studies published in the September 24 New England Journal of Medicine, a high dose of daunorubicin given as part of initial treatment for acute myeloid leukemia (AML) increased the rate of complete remission and, in one study, improved overall survival compared with the standard dose given in the clinic. These beneficial effects of high-dose daunorubicin appeared to be confined to patients aged 65 or younger.
© Vidyya. All rights reserved.
Information appearing on the Vidyya Medical News Service is not intended as a substitute for professional medical care. Seek professional medical help and follow your health care provider's advice.
Interested in subscribing to our daily e-mail newsletter? Send an email to Vidyya@vidyya.com with the word subscribe in the subject field.